Navigation Links
Doxil in Medical News

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer

...e FDA. About DOXIL(R) ( ) doxil is indicated for the treatment of patients with ov...d or recurred after prior platinum-based therapy. doxil in combination with VELCADE(R) (bortezomib) is ind...ADE and have received at least one prior therapy. doxil is also indicated for the treatment of AIDS-relate...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

... Myeloma II-5 Velcade(R) (Bortezomib) II-5 Thalomid(R) (Thalidomide) II-5 Revlimid(R) (Lenalidomide) II-6 Alkeran (Melphalan) II-6 doxil (Liposomal Doxorubicin) II-6 Trisenox(R) (Arsenic trioxide) II-6 Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons ...

Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results

...on, the Company submitted two New Drug Applications to the FDA: trabectedin (known as YONDELIS outside the U.S.) when administered in combination with doxil for the treatment of women with relapsed ovarian cancer and carisbamate, a new investigational compound for the adjunctive treatment of partial onset ...

Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer

...cer (ROC). If approved, trabectedin combined with doxil will provide a new, non-platinum treatment option ... ROC, comparing the combination of trabectedin and doxil to doxil alone in 672 patients. The study showed that pati...

Johnson & Johnson Reports 2008 Third-Quarter Results:

... patients undergoing hip or knee replacement surgery. The Company also submitted a supplemental new drug application to the FDA for the combination of doxil and Taxotere(R) for the treatment of women with advanced breast cancer who have received prior anthracycline treatment. In July, the FDA granted pedia...

Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients

...gestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase III, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Velcade(R) Plus Doxil(R) Improves Previously Treated Multiple Myeloma Patients

...de effects such as neuropathy with the addition of doxil to the VELCADE. The findings were presented at the...idence that VELCADE increases the effectiveness of doxil against cancer cells and doxil does the same for VELCADE. "'Improved surv...
Doxil in Medical Technology

Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma

Data Presented at the ASCO Cancer Conference NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said that d...

Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells

...eligible will be treated with Doxil(R) (pegylated liposomal doxorubicin), an approved drug used to treat ovarian cancer, or with EC145, which combines doxil with folate (vitamin B-9). The PRECEDENT study is yet another example of CTCA's commitment to expanding medical treatment options for women bat...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... The study found that patients treated with the doxil and docetaxel combination had a 35% risk reduction...tudy. "The study suggests that the combination of doxil and docetaxel may be an effective treatment for pa...e randomly assigned to one of two treatment arms: doxil 30 mg/m2 followed by docetaxel 60 mg/m2 on the fir...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

...percent prior to transplant and 72 percent post-transplant -- VELCADE, doxil and dexamethasone (PAD or VcDD) prior to transplant showed a CR rate of...6 evaluable patients who received VELCADE at 1.3 mg/m2 on days 1, 4, 8, 11, doxil at 30 mg/m2 on day 4 and dexamethasone at 40 mg on days 1 through 4, 8 thro...

Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...k, L. E. Fayad, J. Durand About DOXIL(R) doxil is indicated in combination with VELCADE(R) (borte...ver impairment, Substitution -- The use of doxil may lead to cardiac toxicity. Myocardial damage ma...ions -- Severe myelosuppression may occur -- doxil dosage should be reduced in patients with impaired...

Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma

...gestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase III, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

...-- Phase I/II Study of Rituxan in Combination with doxil in Patients with Relapsing or Refractory B-Cel...- Preliminary Results of a Phase II Study of HCVID doxil Alternated with Methotrexate-Cytarabine in Pat...68 [accepted as abstract only]) About DOXIL doxil in combination with VELCADE(R) (bortezomib) for In...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

...alone, the current standard of care. The VELCADE + doxil abstract was selected by the Best of the American ...e (Abstract #8002) "The combination of VELCADE + doxil is highly active, with the time to disease progres...fficacy and safety of the combination of VELCADE + doxil to VELCADE monotherapy, the standard of care in pa...

Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer

...portant Safety Information from the U.S. label for doxil Myocardial damage may lead to congestive heart fa...f doxorubicin HCl approaches 550 mg/m2. The use of doxil may lead to cardiac toxicity. Prior use of other a...are receiving concurrent cyclophosphamide therapy. doxil should be administered to patients with a history ...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

...en in previous VELCADE clinical trials. Combination Therapy with VELCADE, doxil and Dexamethasone in Newly Diagnosed Myeloma: Updated Results of a Phase II...mg/m(2) on days 1, 4, 8 and 11 of a 21-day schedule. Patients also received doxil at 30 mg/m(2) on day 4 and dexamethasone at 40 mg on days 1 through 4 or 20...
Doxil in Biological Technology

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...n Hospital, Sutton, United Kingdom About doxil (R) (doxorubicin HCl liposome injection) doxil is indicated for the treatment of patients with ov...d or recurred after prior platinum based therapy. doxil in combination with VELCADE(R) (bortezomib) is ind...

Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Medivation Announces Senior Management Promotions

...ntal therapeutics. She joined Chiron Corporation from SEQUUS Pharmaceuticals where she was responsible for the development and accelerated approval of doxil for the treatment of ovarian cancer. Dr. Bronson began her career in drug development at Cato Research, a contract research organization. She earned a...

Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...
Other Tags
(Date:9/1/2014)... September 02, 2014 NAPW ... Healthcare, LLC as a 2014 Professional Woman of the ... for leadership in office management. As the largest, most-recognized ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
(Date:9/1/2014)... NAPW honors ... Orthopedics Pain Treatment & Cardiology, as a ... is recognized with this prestigious distinction for leadership ... organization of women in the country, spanning virtually ... Professional Women is a powerfully vibrant networking community ...
(Date:9/1/2014)... (PRWEB) September 02, 2014 Spine Team ... annual Reader’s Choice ‘Best of 2014’ award based on ... Northeast Tarrant County, Las Colinas & Coppell, Rockwall & ... would like to thank our patients and the residents ... Texas as LIVING magazine’s ‘Best of 2014’ in the ...
(Date:9/1/2014)... an innovative Washington State University study of deadly force ... black people. But when it came time to shoot, ... longer to pull the trigger against them than against ... the recent Journal of Experimental Criminology , grow ... disproportionate number of ethnic and racial minorities shot by ...
(Date:9/1/2014)... UWDress.com, a well-known wedding dress manufacturer and ... green bridesmaid dresses for its new and old ... company’s online category. What’s more, they are offered at ... offer is specially launched to celebrate the coming of ... have won great appreciation from worldwide clients. Now, the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Laura Brinkley, Manager, Gibson Orthopedics Pain Treatment & Cardiology Clinic, a 2014 Professional Woman of the Year 2Health News:Spine Team Texas chosen in LIVING Magazine’s Reader’s Choice Awards 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 3Health News:2014 Lime Green Bridesmaid Dresses Offered At UWDress.com 2
(Date:8/31/2014)... is developing drugs that are highly effective against a ... patient. Such properties are directly related to the 3D ... have a shape that is perfectly complementary to a ... specificity. Publishing in Nature Chemistry , EPFL scientists ... the 3D structure of bioactive peptides and enhance their ...
(Date:8/31/2014)... is available in French . ... just published in the prestigious Nature Neuroscience journal ... Centre of the Douglas Mental Health University Institute and McGill ... circuitry and dynamic mechanisms controlling memory as well of the ... sub-region named the subiculum. , In 2009, they developed ...
(Date:8/29/2014)... how the repeated climatic shifts over the last ... genetic diversity, a team of researchers led by ... Carnaval developed a new biodiversity metric called "phylogeographic ... the genetic variation within species is restricted in ... of biology, and 14 other researchers from institutions ...
Breaking Biology News(10 mins):A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2CCNY team defines new biodiversity metric 2
Other Contents